About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

As filed with the Securities and Exchange Commission on December 11, 2025 Registration No. 333-____________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas K. Equels Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Name, address, including zip code, and tele ...

Core Point - The Aviation Institute of Maintenance (AIM) will be the first aircraft maintenance trade school featured on Season 16 of Amazon Prime Video's The College Tour, indicating a significant milestone for the institution and the growing interest in aviation maintenance careers and skilled trades education [1] Group 1 - AIM's filming will commence on December 8, 2025, at its Hasbrouck Heights campus, showcasing the school's commitment to promoting aviation maintenance education [1] - The feature on a popular streaming platform reflects the increasing national momentum behind careers in aviation maintenance and skilled trades [1]

AIM ImmunoTech Conference Summary Company Overview - **Company**: AIM ImmunoTech (NYSEAM:AIM) - **Lead Asset**: Ampligen, a drug with potential in immuno-oncology, effective as both a monotherapy and a synergistic enhancer to checkpoint inhibitors across various solid tumors [8][12] Core Points and Arguments - **Ampligen's Potential**: - Demonstrated strong impact in improving response rates for patients who are refractory to checkpoint inhibitors [8] - Alters tumor microenvironment to enhance visibility to immune system, transforming "cold tumors" into "hot tumors" [11][12] - **Strategic Focus on Pancreatic Cancer**: - AIM has prioritized pancreatic cancer as its lead indication due to the high unmet medical need and potential for significant impact on patient survival [13][15] - The company aims to leverage its data showing Ampligen's ability to extend overall survival in pancreatic cancer, both as a monotherapy and in combination with AstraZeneca's Durvalumab [15][19] - Orphan drug designations received in the U.S. and Europe provide market exclusivity, enhancing the business opportunity [16][17] - **Market Context**: - Over 500,000 deaths annually from pancreatic cancer, with a low survival rate, highlighting the critical need for effective treatments [19] - The oncology sector is where significant biotech deals occur, with potential for billion-dollar partnerships [14][28] - **Clinical and Regulatory Strategy**: - AIM is working towards initiating a Phase 3 trial in pancreatic cancer, ideally in conjunction with checkpoint inhibitors [24][25] - The company has treated 57 subjects, demonstrating the ability to extend overall survival beyond standard care [25] - **Upcoming Milestones**: - Anticipation of a positive year-end report, which is expected to be a significant inflection point for the company [28] - Plans to find a big pharma partner to support the Phase 3 trial and capitalize on the research and development efforts [26][28] Other Important Content - **Collaborations**: - Successful collaborations with Merck and AstraZeneca have been crucial for advancing Ampligen's development [30] - Data from independent research institutions supports the efficacy of Ampligen in various cancers, not limited to pancreatic cancer [29][30] - **Quality of Life Considerations**: - Ampligen is noted for improving the quality of life for patients undergoing treatment, which is particularly important for those facing severe malignancies [15][16] - **Company's Position**: - AIM is a small biotech company with limited resources but is making significant strides in oncology research [31] - The CEO expressed gratitude towards collaborators, investors, and the research community for their support [39][40] This summary encapsulates the key insights from the AIM ImmunoTech conference, focusing on the company's strategic direction, clinical developments, and market opportunities in the context of pancreatic cancer and broader oncology applications.

Core Viewpoint - AI-Media has launched a comprehensive ADA Title II compliance program to assist U.S. state and local governments in meeting the latest federal digital accessibility requirements [1][2]. Group 1: Compliance Program Details - The ADA Title II Web and Mobile Accessibility Rule requires all digital services of public entities to comply with WCAG 2.1 AA standards, with compliance deadlines set for April 24, 2026, for entities serving over 50,000 people, and April 26, 2027, for smaller jurisdictions [1]. - AI-Media's compliance initiative includes a multi-month educational campaign providing practical tools and promoting solutions to streamline the compliance process [1][2]. Group 2: Technology and Solutions - AI-Media emphasizes two flagship technologies, LEXI Text and LEXI AD, which are AI-driven solutions for real-time captioning and audio description, crucial for achieving ADA compliance [2][3]. - The company has released a checklist of ten key points for ADA compliance, aligning with its Government Solutions program to support public entities with scalable technology and predictable cost models [2]. Group 3: Upcoming Events - AI-Media will host a national webinar on January 20, 2026, titled "ADA Title II - Achieving Compliance with Ease through AI," focusing on the accessibility requirements outlined in WCAG 2.1 AA standards [3]. Group 4: Company Overview - AI-Media (ASX: AIM) is a global leader in AI-driven speech translation, captioning, and language orchestration, providing reliable services that enhance communication efficiency and modern workflows [4].

Core Insights - AI-Media has launched an ADA Title II Compliance Initiative to assist state and local governments in meeting new federal accessibility requirements for digital content [1][4] - The U.S. Department of Justice finalized the ADA Title II Web and Mobile Accessibility Rule, mandating compliance with WCAG 2.1 Level AA, with deadlines starting April 24, 2026, for larger entities [2] - AI-Media's initiative includes a 10-Point ADA Title II Compliance Checklist and highlights its LEXI Text and LEXI AD technologies as essential tools for compliance [4][6] Compliance Initiative - The initiative aims to provide educational resources and practical tools to help government agencies prepare for upcoming compliance deadlines [3] - AI-Media will host a national webinar on January 20, 2026, to discuss accessibility requirements and how AI solutions can facilitate compliance [5] Technology Solutions - LEXI Text offers AI-powered captioning and transcription services to meet WCAG captioning and transcript requirements [11] - LEXI AD provides AI-driven audio description with advanced customization options, crucial for meeting WCAG 2.1 AA standards for prerecorded video [11]

Core Insights - AIM ImmunoTech will participate in the Virtual Investor Closing Bell Series on December 4, 2025, featuring CEO Thomas K. Equels [1] - The discussion will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, particularly the DURIPANC clinical trial in collaboration with AstraZeneca for metastatic pancreatic cancer [2] - The importance of a completed Phase 2 clinical trial with Merck, showing the combination of Ampligen and Keytruda was well-tolerated and beneficial for advanced recurrent ovarian cancer, will also be highlighted [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [4]

Core Insights - AIM ImmunoTech Inc. reported solid clinical and operational execution in Q3 2025, focusing on advancing Ampligen towards FDA approval for pancreatic cancer treatment [2] - Positive mid-year safety and efficacy data from the DURIPANC clinical trial combining Ampligen with AstraZeneca's Imfinzi were highlighted, with a year-end update expected [2] Financial Highlights - As of September 30, 2025, AIM reported cash, cash equivalents, and marketable investments of $2.4 million [8] - Research and development expenses for Q3 2025 were approximately $607,000, a decrease from $1.4 million in Q3 2024 [8] - General and administrative expenses were approximately $1.8 million for Q3 2025, down from $3.1 million in the same period of 2024 [8] - The net loss from operations for Q3 2025 was approximately $(3.3 million), or $(1.57) per share, compared to $(3.7 million), or $(6.00) per share, for Q3 2024 [8] - The company expects a monthly burn rate of approximately $550,000 while maintaining operational efficiencies [8]

Financial Performance - Net loss for the three months ended September 30, 2025, was approximately $3,284,000, a decrease of 11% from $3,700,000 in the same period of 2024[221] - The company incurred a net loss of approximately $9,783,000 for the nine months ended September 30, 2025, a decrease of 14% from $11,353,000 in 2024[234] Revenue and Income - Revenues from the Ampligen® Cost Recovery Program decreased to $26,000 for the three months ended September 30, 2025, down from $35,000 in 2024, reflecting a decrease of $9,000[223] - Interest and other income increased significantly to approximately $3,052,000 for the three months ended September 30, 2025, compared to $718,000 in 2024, an increase of approximately $2,334,000[225] Expenses - Research and Development costs decreased to approximately $607,000 for the three months ended September 30, 2025, down from $1,437,000 in 2024, reflecting a decrease of approximately $830,000[228] - General and Administrative expenses decreased to approximately $1,798,000 for the three months ended September 30, 2025, from $3,079,000 in 2024, a reduction of approximately $1,281,000[229] Cash Flow - Cash used in operating activities for the nine months ended September 30, 2025, was approximately $8,971,000, a decrease of $1,962,000 from $10,933,000 in 2024[247] - Cash provided by financing activities increased to approximately $7,669,000 for the nine months ended September 30, 2025, compared to $5,407,000 in 2024, an increase of $2,262,000[249] - As of September 30, 2025, the company had approximately $2,409,000 in cash and cash equivalents, a decrease of approximately $1,568,000 from December 31, 2024[250] Stockholder Equity and Compliance - As of September 30, 2025, the company's stockholders' deficit was approximately ($6,077,000), necessitating an increase in stockholders' equity to at least $6,000,000 to regain compliance with exchange listing requirements[259] - The company is required to maintain Stockholders Equity of $6,000,000 to comply with NYSE American continued listing requirements[295] Securities and Financing Activities - The company filed a Universal Shelf Registration Statement to register the offering of up to $100,000,000 of various securities, which has not yet been declared effective[262] - An Equity Distribution Agreement with Maxim allows the company to issue and sell up to $3,000,000 of common stock, with a commission of 3.0% on gross proceeds from each sale[263][266] - The company has entered into a Purchase Agreement with Atlas Sciences, committing to purchase up to $15,000,000 of common stock, with the registration statement declared effective on May 1, 2024[272][273] - As of September 30, 2025, a total of 30,829 shares have been issued under the Purchase Agreement for approximately $398,000 after clearing costs[282] - On June 3, 2024, the company issued 56,410 shares of common stock and warrants to a single accredited investor, with warrants exercisable at $36.30 per share[283] - The company received approximately $1,260,000 in gross proceeds from the Transactions before deducting fees to the Placement Agent and other estimated offering expenses[290] - The company issued 46,530 shares of common stock at a purchase price of $28.00 per share in a registered direct offering[289] - The Class E and F warrants were issued at a combined public offering price of $4.00 per share, with gross proceeds of approximately $8,000,000 before deducting placement agent fees and offering expenses[293] - The exercise price for the Class C and Class D Warrants is set at $28.00, and they are not exercisable until December 3, 2024[291] - The Common Warrants have an allocated proceeds total of approximately $2,500,000, with no warrants exercised for the nine months ended September 30, 2025[288] - The Class E and F Warrants were classified as liabilities on the balance sheet as they may require the company to issue additional stock under certain circumstances[294] - The Placement Agent received a cash fee of 8% of the aggregate gross proceeds from the securities sold in the Transactions[287] - The registration statement for the resale of Common Warrant Shares was declared effective by the SEC on July 11, 2024[286] Other Financial Obligations - The company recognized losses from warrant issuances of $4,410,000 during the nine months ended September 30, 2025[234] - The company has an outstanding deposit of $240,000 as of September 30, 2025, which may be used to offset future clinical research expenditures[256] - The company entered into a Forbearance Agreement with a lender, resulting in an outstanding balance of $2,484,000 after applying a 1% fee[257] - The company has a lock-up agreement preventing executive officers and directors from selling securities for 90 days following the closing of the Transactions[285]

Core Insights - AIM ImmunoTech Inc. presented data from a Phase 2 clinical study on Ampligen for advanced recurrent ovarian cancer, showing promising results at the 40th Annual SITC Meeting [1][2] Study Results - The study involved 27 platinum-sensitive patients, with 24 evaluable for response; 5 achieved complete response and 7 had partial response, resulting in an Objective Response Rate (ORR) of 50% [2] - This ORR is significantly higher compared to previous studies, such as Keynote-100, which reported ORRs of 7.4% and 9.9% for pembrolizumab alone [2] Mechanism and Potential - AIM believes that Ampligen can act synergistically with checkpoint inhibitors, potentially benefiting patients who do not respond to these therapies alone [3] - The study's findings suggest that Ampligen may enhance traditional cancer treatments, improving immune responses and prolonging remission for patients with limited options [4] Intellectual Property - AIM holds several patents related to the use of Ampligen in combination with checkpoint inhibitors, with expiration dates ranging from 2039 to 2040 in various jurisdictions [5] Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for cancers, immune disorders, and viral diseases, with Ampligen as its lead investigational drug [7]